<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="965">
  <stage>Registered</stage>
  <submitdate>21/12/2005</submitdate>
  <approvaldate>4/01/2006</approvaldate>
  <actrnumber>ACTRN12606000003572</actrnumber>
  <trial_identification>
    <studytitle>Effects of ramipril on platelet responsiveness to nitric oxide donors.A randomised,placebo controlled, double blind study in patients with high cardiovascular risk.</studytitle>
    <scientifictitle>Effects of ramipril on platelet responsiveness to nitric oxide donors.A randomised,placebo controlled, double blind study in patients with high cardiovascular risk.</scientifictitle>
    <utrn />
    <trialacronym>Nil</trialacronym>
    <secondaryid>Aventis pharmaceuticals</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>High cardiovascular risk</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Ramipril 10mg for 12 weeks</interventions>
    <comparator>Placebo for 12 weeks</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Changes in platelet responsiveness to SNP </outcome>
      <timepoint>After 12 weeks of ramipril therapy</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Effects of ACE inhibitors on arterial compliance.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effects of ACE inhibitors on platelet reponsiveness to SNP.</outcome>
      <timepoint>After 4 weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effects of ACE inhibitors on measures of oxidative stress.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Have pmh of CAD,PVD or stroke or who have diabetes plus at least 1 CV risk(HOPE).</inclusivecriteria>
    <inclusiveminage>55</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>ACE or ARB therapy or need to start same or contraindications to same.Less than 2 Ohms of ADP induced platelet aggregation at baseline.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Unblinded pharmacist used for treatment allocation.Numbered containers were allocated to patients via fax to central pharmacist.</concealment>
    <sequence>Sequence generated via computer in permuted blocks.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/01/2003</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>120</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>The Queen Elizabeth Hospital Cardiology Department</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>United Kingdom</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Aventis pharmaceuticals</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>NA</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To see by what means or mechanism  ACE inhibitors reduce the chance of heart attack or stoke</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Queen Elizabeth Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor John Horowitz</name>
      <address>The Queen Elizabeth Hospital
28 Woodville Road
Woodville SA 5011</address>
      <phone>+61 8 82226000</phone>
      <fax>+61 8 82227021</fax>
      <email>sue.lesie@nwahs.sa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sue Leslie</name>
      <address>The Queen Elizabeth Hospital
28 Woodville Road
Woodville SA 5011</address>
      <phone>+61 8 82226000</phone>
      <fax>+61 8 82227021</fax>
      <email>sue.leslie@nwahs.sa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>